Buntanetap/Posiphen + Placebo

Phase 2/3Completed

0 views this week 0 watching💤 Quiet

Interest: 28/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Alzheimer Disease

Conditions

Alzheimer Disease

Trial Timeline

Apr 1, 2023 → Feb 13, 2024

NCT ID

NCT05686044

About Buntanetap/Posiphen + Placebo

Buntanetap/Posiphen + Placebo is a phase 2/3 stage product being developed by Annovis Bio for Alzheimer Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05686044. Target conditions include Alzheimer Disease.

What happened to similar drugs?

20 of 20 similar drugs in Alzheimer Disease were approved

Approved (20) Terminated (2) Active (0)

✅Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved

✅DonepezilEisaiApproved

✅DONEPEZIL HYDROCHLORIDEEisaiApproved

✅Donepezil HCLEisaiApproved

✅Donepezil HClEisaiApproved

✅Donepezil HydrochlorideEisaiApproved

✅AriceptEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06709014	Phase 3	Recruiting	Feb 4, 2025	Jun 1, 2028	Early Alzheimers Disease
NCT05686044	Phase 2/3	Completed	Apr 1, 2023	Feb 13, 2024	Alzheimer Disease
NCT05357989	Phase 3	Completed	Aug 3, 2022	Dec 4, 2023	Parkinson's Disease, Idiopathic

Competing Products

20 competing products in Alzheimer Disease

See all competitors

Product	Company	Stage	Hype Score
[18F]NAV4694	Navidea Biopharmaceuticals	Phase 2	21
Bromocriptine Mesilate + Placebos	Towa Pharmaceutical	Phase 1/2	32
LY450139 + Placebo	Eli Lilly	Phase 3	40
Solanezumab + Placebo	Eli Lilly	Phase 3	32
LY450139 dihydrate + placebo	Eli Lilly	Phase 2	35
Zagotenemab + Placebo	Eli Lilly	Phase 2	35
Donanemab + Placebo + LY3202626	Eli Lilly	Phase 2	35
Donanemab + Placebo	Eli Lilly	Phase 3	47
GSK4527226	Alector	Phase 2	29
AL002 + Placebo	Alector	Phase 2	25
GSK4527226	Alector	Phase 2	32
AL002	Alector	Phase 2	17
Solanezumab + Placebo	Eli Lilly	Phase 3	32
donanemab	Eli Lilly	Phase 2	35
ATH-1017	LeonaBio	Phase 2/3	20
ATH-1017 + Placebo	LeonaBio	Phase 2/3	28
ATH-1017 + Placebo	LeonaBio	Phase 2	25
NDX-1017 + Placebo	LeonaBio	Phase 1	19
simufilam	Cassava Sciences	Phase 2	17
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125	Cassava Sciences	Phase 1	19